Eledon Pharmaceuticals, Inc. (ELDN) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Eledon Pharmaceuticals, Inc. (ELDN) Bundle
Enhance your investment strategies with the Eledon Pharmaceuticals, Inc. (ELDN) DCF Calculator! Explore authentic financial data, adjust growth projections and expenses, and instantly visualize how these changes affect the intrinsic value of Eledon Pharmaceuticals, Inc. (ELDN).
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | -100 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -15.8 | -23.0 | -36.7 | -87.6 | .0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | -19193.33 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .2 | .2 | .2 | .4 | 43.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 152.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -16.0 | -23.2 | -36.9 | -88.0 | -43.0 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | -19345.83 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 8.8 | 114.2 | 84.8 | 56.4 | 51.1 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 91.67 | 100 | 100 | 100 | 98.33 | 98.33 | 98.33 | 98.33 | 98.33 |
Inventories | .9 | 1.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 1072.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .3 | 1.4 | 1.8 | 2.2 | 1.0 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 1138.33 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -17.9 | -22.8 | -34.5 | -87.5 | -43.0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -18.5 | -21.9 | -32.5 | -86.7 | -1.2 | -1.0 | .0 | .0 | .0 | .0 |
WACC, % | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 | 8.05 |
PV UFCF | ||||||||||
SUM PV UFCF | -.9 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -4 | |||||||||
Equity Value | 3 | |||||||||
Diluted Shares Outstanding, MM | 25 | |||||||||
Equity Value Per Share | 0.14 |
What You Will Get
- Comprehensive ELDN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are automatically computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Eledon Pharmaceuticals' future performance.
- User-Friendly Design: Created for industry professionals while remaining accessible to newcomers.
Key Features
- Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Eledon Pharmaceuticals, Inc. (ELDN).
- WACC Analysis Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to ELDN.
- Customizable Forecast Inputs: Easily adjust growth projections, capital expenditures, and discount rates to fit Eledon’s business model.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Eledon Pharmaceuticals, Inc. (ELDN).
- Interactive Dashboard and Visualizations: Graphical representations highlight essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Eledon Pharmaceuticals, Inc. (ELDN) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including the intrinsic value of Eledon Pharmaceuticals, Inc. (ELDN).
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by researchers, financial analysts, and industry leaders.
- Comprehensive Data: Eledon's historical and projected financials preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Should Use This Product?
- Investors: Accurately estimate Eledon's fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Eledon Pharmaceuticals.
- Consultants: Quickly customize the template for valuation reports tailored to Eledon Pharmaceuticals' clients.
- Entrepreneurs: Gain insights into financial modeling techniques employed by leading pharmaceutical companies.
- Educators: Use it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Eledon Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Eledon Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.